<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id><journal-id journal-id-type="pmc-domain-id">567</journal-id><journal-id journal-id-type="pmc-domain">jbc</journal-id><journal-id journal-id-type="publisher-id">JBC</journal-id><journal-title-group><journal-title>The Journal of Biological Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4192497</article-id><article-id pub-id-type="pmcid-ver">PMC4192497.1</article-id><article-id pub-id-type="pmcaid">4192497</article-id><article-id pub-id-type="pmcaiid">4192497</article-id><article-id pub-id-type="pmid">25148681</article-id><article-id pub-id-type="doi">10.1074/jbc.M114.584342</article-id><article-id pub-id-type="publisher-id">M114.584342</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Neurobiology</subject></subj-group></article-categories><title-group><article-title>Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrP<sup>C</sup>) and Metabotropic Glutamate Receptor 5 (mGluR5)<xref ref-type="fn" rid="FN1">*</xref></article-title><alt-title alt-title-type="short">Therapeutic Modulation of the PrP<sup>C</sup>-mGluR5 Interaction</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Haas</surname><given-names initials="LT">Laura T.</given-names></name><xref ref-type="aff" rid="aff1"><sup>‡</sup></xref><xref ref-type="aff" rid="aff2"><sup>§</sup></xref><xref ref-type="author-notes" rid="FN2"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kostylev</surname><given-names initials="MA">Mikhail A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>‡</sup></xref><xref ref-type="author-notes" rid="FN2"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Strittmatter</surname><given-names initials="SM">Stephen M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>‡</sup></xref><xref ref-type="corresp" rid="cor1"><sup>2</sup></xref></contrib><aff id="aff1">From the <label>‡</label>Cellular Neuroscience, Neurodegeneration and Repair Program, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut 06536 and </aff><aff id="aff2">the <label>§</label>Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, D-72074 Tübingen, Germany</aff></contrib-group><author-notes><corresp id="cor1"><label>2</label> To whom correspondence should be addressed: <addr-line>Cellular Neuroscience, Neurodegeneration and Repair Program, Yale University School of Medicine, 295 Congress Ave., New Haven, CT 06536.</addr-line> E-mail: <email>stephen.strittmatter@yale.edu</email>.</corresp><fn fn-type="equal" id="FN2"><label>1</label><p>Both authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><day>10</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2014</year></pub-date><volume>289</volume><issue>41</issue><issue-id pub-id-type="pmc-issue-id">243734</issue-id><fpage>28460</fpage><lpage>28477</lpage><history><date date-type="received"><day>23</day><month>5</month><year>2014</year></date><date date-type="rev-recd"><day>15</day><month>8</month><year>2014</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>10</month><year>2015</year></date></event><event event-type="pmc-live"><date><day>10</day><month>10</month><year>2015</year></date></event><event event-type="pmc-released-under-embargo"><date><day>11</day><month>08</month><year>2015</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-02-06 14:56:16.713"><day>06</day><month>02</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="zbc28460.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="zbc04114028460.pdf"/><abstract abstract-type="teaser"><p><bold>Background:</bold> Amyloid-β oligomers trigger Alzheimer disease pathophysiology via the interaction of cellular prion protein (PrP<sup>C</sup>) with metabotropic glutamate receptor 5 (mGluR5).</p><p><bold>Results:</bold> PrP<sup>C</sup> region 91–153 interacts preferentially with the activated conformation of mGluR5.</p><p><bold>Conclusion:</bold> Antibodies against PrP<sup>C</sup> region 91–153 and agonist/antagonist-driven mGluR5 conformations regulate the PrP<sup>C</sup>-mGluR5 interaction.</p><p><bold>Significance:</bold> These findings have therapeutic implications for Alzheimer disease by identifying compounds that modulate the PrP<sup>C</sup>-mGluR5 interaction.</p></abstract><abstract><p>Soluble Amyloid-β oligomers (Aβo) can trigger Alzheimer disease (AD) pathophysiology by binding to cell surface cellular prion protein (PrP<sup>C</sup>). PrP<sup>C</sup> interacts physically with metabotropic glutamate receptor 5 (mGluR5), and this interaction controls the transmission of neurotoxic signals to intracellular substrates. Because the interruption of the signal transduction from PrP<sup>C</sup> to mGluR5 has therapeutic potential for AD, we developed assays to explore the effect of endogenous ligands, agonists/antagonists, and antibodies on the interaction between PrP<sup>C</sup> and mGluR5 in cell lines and mouse brain. We show that the PrP<sup>C</sup> segment of amino acids 91–153 mediates the interaction with mGluR5. Agonists of mGluR5 increase the mGluR5-PrP<sup>C</sup> interaction, whereas mGluR5 antagonists suppress protein association. Synthetic Aβo promotes the protein interaction in mouse brain and transfected HEK-293 cell membrane preparations. The interaction of PrP<sup>C</sup> and mGluR5 is enhanced dramatically in the brains of familial AD transgenic model mice. In brain homogenates with Aβo, the interaction of PrP<sup>C</sup> and mGluR5 is reversed by mGluR5-directed antagonists or antibodies directed against the PrP<sup>C</sup> segment of amino acids 91–153. Silent allosteric modulators of mGluR5 do not alter Glu or basal mGluR5 activity, but they disrupt the Aβo-induced interaction of mGluR5 with PrP<sup>C</sup>. The assays described here have the potential to identify and develop new compounds that inhibit the interaction of PrP<sup>C</sup> and mGluR5, which plays a pivotal role in the pathogenesis of Alzheimer disease by transmitting the signal from extracellular Aβo into the cytosol.</p></abstract><kwd-group><kwd>Alzheimer Disease</kwd><kwd>Amyloid-β (AB)</kwd><kwd>Metabotropic Glutamate Receptor (mGluR)</kwd><kwd>Neurodegenerative Disease</kwd><kwd>Prion</kwd><kwd>Protein-Protein Interaction</kwd><kwd>Therapeutic Modulation</kwd></kwd-group><funding-group><award-group><funding-source id="CS100">National Institutes of Health</funding-source><award-id rid="CS100">R01AG034924</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>